Baidu
map

创新联动,赋能未来:罗氏诊断和GE医疗两大巨头于第三届进博会签署战略合作备忘录

2020-11-07 进博会 进博会

日前,医疗界两大巨头——罗氏诊断中国与GE医疗中国于第三届中国国际进口博览会(以下简称:进博会)共同签署了战略合作备忘录。

日前,医疗界两大巨头——罗氏诊断中国与GE医疗中国于第三届中国国际进口博览会(以下简称:进博会)共同签署了战略合作备忘录。双方宣布将围绕渠道层面创新模式搭建、重点疾病诊断领域解决方案应用和落地、以及前瞻性技术研发等方面开展深入合作。本次合作旨在深化中国市场开发伙伴关系,加速更多创新体内体外诊断技术与治疗方案在中国的落地,共同推动建立以精准诊断为基础的创新疾病管理生态圈,造福中国患者。

 
 
通过聚焦以下方面的战略携手,双方致力于联手创新,共同打造技术研发、商业模型和客户解决方案。

1,在渠道上战略互补,优化资源整合,携手打造客户端精准医疗整体解决方案。

2,在重点关注疾病诊断领域中,展开学术交流和联手打造客户端配套解决方案,涵盖肿瘤、妇女健康、心脑血管疾病和传染病等多学科、多病种,共同推动医学诊断新技术的应用与精准诊疗战略的落地。

3,在前瞻性技术研发领域,如5G远程诊断、多学科会诊平台等方面,展开技术交流和产品研发合作。

4,在市场活动,专家资源和客户端学科建设上相互合作,平台共享,共同打造以临床价值和医学创新为核心的解决方案。
 
图为:罗氏诊断中国总经理姚国樑先生
 
罗氏诊断中国总经理姚国樑先生表示:“很高兴在进博会这个国家级展会上,确定与GE医疗的强强联手。我们希望能够充分结合双方在各自精准诊断领域的优势,将更多创新的诊断产品移植到中国,推动多个疾病诊断水平的大跨度提升,造福广大中国患者。我们借助进博会这一重要国际交流展示平台宣布此项战略合作,正是希望通过进博会的放大效应,共同激发以创新为核心的合作动能,加速疾病管理生态圈的建立,助力实现‘健康中国2030’蓝图。” 
 
图为:GE医疗中国总裁兼首席执行官张轶昊先生
 
GE医疗中国总裁兼首席执行官张轶昊先生表示:“很高兴能够在第三届进博会上与罗氏诊断再次携手,在全球合作的基础上,整合双方体内外诊断的优势,赋能临床诊疗。作为引领精准医疗的创新者,我们在中国的使命是关爱每个中国人的生命重要时刻。与罗氏诊断的合作也意味着我们‘合作共赢’战略更进一步,这不仅将会为会临床医学带来一大促动,拓宽创新疾病管理生态圈,更会为广大中国患者带来更精准的关爱。”

作为体外诊断领先企业,罗氏诊断致力于开发和提供从疾病的早期发现、预防到诊断、监测的创新、高性价比、及时和可靠的诊断系统和解决方案,从而帮助医务人员提高患者的治疗效果,改善人们生活质量,并减少社会医疗成本。今年,罗氏诊断携手罗氏制药,再度联袂参展第三届中国国际进口博览会,在7.1医疗器械及医药保健展区集中展示罗氏集团的创新产品和覆盖疾病诊疗过程的全面解决方案。此外,在今年特设的公共卫生防疫专区中,罗氏诊断将首次集中展示数款抗击新冠疫情的诊断解决方案,包括核酸检测、抗体抗原检测等,展现其对于全球抗疫的快速响应和积极贡献。

GE医疗是业界领先的医学成像、监护、数字医疗技术创新者。1979年进入中国以来,GE医疗持续深化研发、产品、渠道、服务和供应链的国产战略,为中国患者提供智能设备、数据分析、软件应用和服务,实现从疾病诊断、治疗到监护全方位的精准医疗。作为GE核心业务板块之一,GE医疗今年以“关爱每个中国人生命重要时刻”为主题参与第三届中国国际进口博览会,同时亮相8.1医疗器械及医药保健展区和4.1装备展馆,旨在把全球同步的创新技术和产品带给中国医院和病患,助力中国医疗行业解决在公共卫生防疫、重大疾病精准诊治、医疗可及性和基层医疗普惠等领域的迫切需求。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1285945, encodeId=107e12859457f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379873, encodeId=84e513e987361, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394718, encodeId=7e371394e18c0, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478267, encodeId=eeda14e8267f5, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1285945, encodeId=107e12859457f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379873, encodeId=84e513e987361, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394718, encodeId=7e371394e18c0, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478267, encodeId=eeda14e8267f5, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1285945, encodeId=107e12859457f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379873, encodeId=84e513e987361, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394718, encodeId=7e371394e18c0, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478267, encodeId=eeda14e8267f5, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1285945, encodeId=107e12859457f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379873, encodeId=84e513e987361, content=<a href='/topic/show?id=6c429434937' target=_blank style='color:#2F92EE;'>#进博会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94349, encryptionId=6c429434937, topicName=进博会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394718, encodeId=7e371394e18c0, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478267, encodeId=eeda14e8267f5, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Nov 08 15:24:32 CST 2020, time=2020-11-08, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map